Skip to main content
SpringerLink
Log in
Book cover

Cell Death Signaling in Cancer Biology and Treatment pp 35–51Cite as

The Warburg Effect and Beyond: Metabolic Dependencies for Cancer Cells

  • Chapter
  • First Online:

Part of the book series: Cell Death in Biology and Diseases ((CELLDEATH))

Abstract

Current definitions of cancer are best realized as a list of traits or hallmarks, such as tissue invasion, metastasis, cell-autonomous growth, and resistance to apoptosis. A recent update included deregulated cellular energetics as an emerging hallmark. However, debate about tumor cell metabolism occupied center stage in the pre-oncogene era. Over the last 15 years, direct links of oncogenes and tumor suppressor genes to cell metabolism have brought cancer metabolism to the forefront once again. Current tools provide much greater opportunities for probing metabolic differences between normal and cancer cells, in some cases revealing flux through unexpected metabolic pathways. Metabolic networks may also be truncated, presenting opportunities for selective growth inhibition or death by targeting non-redundant pathways in cancer cells. These “metabolic dependencies” are not likely to be associated with classically defined oncogenes or computationally derived drivers and thus may require novel strategies for discovery.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Warburg O (1956) On the origin of cancer cells. Science 123(3191):309–314

    Article  CAS  PubMed  Google Scholar 

  2. Warburg O (1956) On respiratory impairment in cancer cells. Science 124(3215):269–270

    CAS  PubMed  Google Scholar 

  3. Wu M, Neilson A, Swift AL, Moran R, Tamagnine J, Parslow D, Armistead S, Lemire K, Orrell J, Teich J, Chomicz S, Ferrick DA (2007) Multiparameter metabolic analysis reveals a close link between attenuated mitochondrial function and enhanced glycolytic dependency in human tumor cells. Am J Physiol Cell Physiol 292(1):C125–C136

    Article  CAS  PubMed  Google Scholar 

  4. Pedersen PL, Greenawalt JW, Chan TL, Morris HP (1970) A comparison of some ultrastructural and biochemical properties of mitochondria from Morris hepatomas 9618A, 7800, and 3924A. Cancer Res 30(11):2620–2626

    CAS  PubMed  Google Scholar 

  5. Eboli ML, Paradies G, Galeotti T, Papa S (1977) Pyruvate transport in tumour-cell mitochondria. Biochim Biophys Acta 460(1):183–187

    Article  CAS  PubMed  Google Scholar 

  6. Isidoro A, Casado E, Redondo A, Acebo P, Espinosa E, Alonso AM, Cejas P, Hardisson D, Fresno Vara JA, Belda-Iniesta C, Gonzalez-Baron M, Cuezva JM (2005) Breast carcinomas fulfill the warburg hypothesis and provide metabolic markers of cancer prognosis. Carcinog 26(12):2095–2104

    Article  CAS  Google Scholar 

  7. Cuezva JM, Krajewska M, de Heredia ML, Krajewski S, Santamaria G, Kim H, Zapata JM, Marusawa H, Chamorro M, Reed JC (2002) The bioenergetics signature of cancer: a marker of tumor progression. Cancer Res 62(22):6674–6681

    CAS  PubMed  Google Scholar 

  8. Cuezva JM, Chen G, Alonso AM, Isidoro A, Misek DE, Hanash SM, Beer DG (2004) The bioenergetics signature of lung carcinomas is a molecular marker of cancer diagnosis and prognosis. Carcinog 25(7):1157–1163

    Article  CAS  Google Scholar 

  9. Sanchez-Cenizo L, Formentini L, Aldea M, Ortega AD, Garcia-Huerta P, Sanchez-Arago M, Cuezva JM (2010) Up-regulation of the ATPase inhibitory factor (IF1) of the mitochondrial H+ -ATP synthase in human tumors mediates the metabolic shift of cancer cells to a Warburg phenotype. J Biol Chem 285(33):25308–25313

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  10. Crabtree JG (1929) Observations on the carbohydrate metabolism of tumours. Biochem J 23(3):536–545

    CAS  PubMed Central  PubMed  Google Scholar 

  11. Formentini L, Sanchez-Arago M, Sanchez-Cenizo L, Cuezva JM (2012) The mitochondrial ATPase inhibitory factor 1 triggers a ROS-mediated retrograde prosurvival and proliferative response. Mol Cell 45(6):731–742

    Article  CAS  PubMed  Google Scholar 

  12. Sussman I, Erecinska M, Wilson DF (1980) Regulation of cellular energy metabolism: the crabtree effect. Biochim Biophys Acta 591(2):209–223

    Article  CAS  PubMed  Google Scholar 

  13. Wu R, Racker E (1959) Regulatory mechanisms in carbohydrate metabolism. IV. Pasteur effect and crabtree effect in ascites tumor cells. J Biol Chem 234(5):1036–1041

    CAS  PubMed  Google Scholar 

  14. Chesney J, Mitchell R, Benigni F, Bacher M, Spiegel L, Al-Abed Y, Han JH, Metz C, Bucala R (1999) An inducible gene product for 6-phosphofructo-2-kinase with an AU-rich instability element: role in tumor cell glycolysis and the warburg effect. Proc Natl Acad Sci U S A 96(6):3047–3052

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  15. Guppy M, Greiner E, Brand K (1993) The role of the crabtree effect and an endogenous fuel in the energy metabolism of resting and proliferating thymocytes. Eur J Biochem 212(1):95–99

    Article  CAS  PubMed  Google Scholar 

  16. Reitzer LJ, Wice BM, Kennell D (1979) Evidence that glutamine, not sugar, is the major energy source for cultured HeLa cells. J Biol Chem 254(8):2669–2676

    CAS  PubMed  Google Scholar 

  17. Vazquez A, Liu J, Zhou Y, Oltvai ZN (2010) Catabolic efficiency of aerobic glycolysis: the warburg effect revisited. BMC Syst Biol 6(5):58

    Article  Google Scholar 

  18. Boxer GE, Devlin TM (1961) Pathways of intracellular hydrogen transport. Science 134(3489):1495–1501

    Article  CAS  PubMed  Google Scholar 

  19. Sato K, Takaya S, Imai F, Hatayama I, Ito N (1978) Different deviation patterns of carbohydrate-metabolizing enzymes in primary rat hepatomas induced by different chemical carcinogens. Cancer Res 38(9):3086–3093

    CAS  PubMed  Google Scholar 

  20. Mazurek S (2011) Pyruvate kinase type M2: a key regulator of the metabolic budget system in tumor cells. Int J Biochem Cell Biol 43(7):969–980

    Article  CAS  PubMed  Google Scholar 

  21. Hitosugi T, Kang S, Vander Heiden MG, Chung TW, Elf S, Lythgoe K, Dong S, Lonial S, Wang X, Chen GZ, Xie J, Gu TL, Polakiewicz RD, Roesel JL, Boggon TJ, Khuri FR, Gilliland DG, Cantley LC, Kaufman J, Chen J (2009) Tyrosine phosphorylation inhibits PKM2 to promote the warburg effect and tumor growth. Sci Signal 2(97):ra73

    Google Scholar 

  22. Christofk HR, Vander Heiden MG, Wu N, Asara JM, Cantley LC (2008) Pyruvate kinase M2 is a phosphotyrosine-binding protein. Nature 452(7184):181–186

    Article  CAS  PubMed  Google Scholar 

  23. Christofk HR, Vander Heiden MG, Harris MH, Ramanathan A, Gerszten RE, Wei R, Fleming MD, Schreiber SL, Cantley LC (2008) The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 452(7184):230–233

    Article  CAS  PubMed  Google Scholar 

  24. Presek P, Reinacher M, Eigenbrodt E (1988) Pyruvate kinase type M2 is phosphorylated at tyrosine residues in cells transformed by rous sarcoma virus. FEBS Lett 242(1):194–198

    Article  CAS  PubMed  Google Scholar 

  25. Anastasiou D, Poulogiannis G, Asara JM, Boxer MB, Jiang JK, Shen M, Bellinger G, Sasaki AT, Locasale JW, Auld DS, Thomas CJ, Vander Heiden MG, Cantley LC (2011) Inhibition of pyruvate kinase M2 by reactive oxygen species contributes to cellular antioxidant responses. Science 334(6060):1278–1283

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  26. Vander Heiden MG, Locasale JW, Swanson KD, Sharfi H, Heffron GJ, Amador-Noguez D, Christofk HR, Wagner G, Rabinowitz JD, Asara JM, Cantley LC (2010) Evidence for an alternative glycolytic pathway in rapidly proliferating cells. Science 329(5998):1492–1499

    Article  CAS  PubMed  Google Scholar 

  27. Gao X, Wang H, Yang JJ, Liu X, Liu ZR (2012) Pyruvate kinase M2 regulates gene transcription by acting as a protein kinase. Mol Cell 45(5):598–609

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  28. Wellen KE, Lu C, Mancuso A, Lemons JM, Ryczko M, Dennis JW, Rabinowitz JD, Coller HA, Thompson CB (2010) The hexosamine biosynthetic pathway couples growth factor-induced glutamine uptake to glucose metabolism. Genes Dev 24(24):2784–2799

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  29. Shim H, Dolde C, Lewis BC, Wu CS, Dang G, Jungmann RA, Dalla-Favera R, Dang CV (1997) c-Myc transactivation of LDH-A: implications for tumor metabolism and growth. Proc Natl Acad Sci U S A 94(13):6658–6663

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  30. Morrish F, Neretti N, Sedivy JM, Hockenbery DM (2008) The oncogene c-Myc coordinates regulation of metabolic networks to enable rapid cell cycle entry. Cell Cycle 7(8):1054–1066

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  31. Morrish F, Isern N, Sadilek M, Jeffrey M, Hockenbery DM (2009) c-Myc activates multiple metabolic networks to generate substrates for cell-cycle entry. Oncogene 28(27):2485–2491

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  32. Morrish F, Noonan J, Perez-Olsen C, Gafken PR, Fitzgibbon M, Kelleher J, VanGilst M, Hockenbery D (2010) Myc-dependent mitochondrial generation of acetyl-CoA contributes to fatty acid biosynthesis and histone acetylation during cell cycle entry. J Biol Chem 285(47):36267–36274

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  33. Qing G, Skuli N, Mayes PA, Pawel B, Martinez D, Maris JM, Simon MC (2010) Combinatorial regulation of neuroblastoma tumor progression by N-Myc and hypoxia inducible factor HIF-1 alpha. Cancer Res 70(24):10351–10361

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  34. Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D, Buechler P, Isaacs WB, Semenza GL, Simons JW (1999) Overexpression of hypoxia-inducible factor 1 alpha in common human cancers and their metastases. Cancer Res 59(22):5830–5835

    CAS  PubMed  Google Scholar 

  35. Selak MA, Armour SM, MacKenzie ED, Boulahbel H, Watson DG, Mansfield KD, Pan Y, Simon MC, Thompson CB, Gottlieb E (2005) Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell 7(1):77–85

    Article  CAS  PubMed  Google Scholar 

  36. Lu H, Forbes RA, Verma A (2002) Hypoxia-inducible factor 1 activation by aerobic glycolysis implicates the Warburg effect in carcinogenesis. J Biol Chem 277(26):23111–23115

    Article  CAS  PubMed  Google Scholar 

  37. Treins C, Giorgetti-Peraldi S, Murdaca J, Semenza GL, Van Obberghen E (2002) Insulin stimulates hypoxia-inducible factor 1 through a phosphatidylinositol 3-kinase/target of rapamycin-dependent signaling pathway. J Biol Chem 277(31):27975–27981

    Article  CAS  PubMed  Google Scholar 

  38. Koshiji M, Kageyama Y, Pete EA, Horikawa I, Barrett JC, Huang LE (2004) HIF-1 alpha induces cell cycle arrest by functionally counteracting Myc. EMBO J 23(9):1949–1956

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  39. Kim JW, Gao P, Liu YC, Semenza GL, Dang CV (2007) Hypoxia-inducible factor 1 and dysregulated c-Myc cooperatively induce vascular endothelial growth factor and metabolic switches hexokinase 2 and pyruvate dehydrogenase kinase 1. Mol Cell Biol 27(21):7381–7393

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  40. Zhou QL, Jiang ZY, Holik J, Chawla A, Hagan GN, Leszyk J, Czech MP (2008) Akt substrate TBC1D1 regulates GLUT1 expression through the mTOR pathway in 3T3-L1 adipocytes. Biochem J 411(3):647–655

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  41. Sakamoto K, Holman GD (2008) Emerging role for AS160/TBC1D4 and TBC1D1 in the regulation of GLUT4 traffic. Am J Physiol Endocrinol Metab 295(1):E29–E37

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  42. Deprez J, Vertommen D, Alessi DR, Hue L, Rider MH (1997) Phosphorylation and activation of heart 6-phosphofructo-2-kinase by protein kinase B and other protein kinases of the insulin signaling cascades. J Biol Chem 41(3):533–535

    Google Scholar 

  43. Gottlob K, Majewski N, Kennedy S, Kandel E, Robey RB, Hay N (2001) Inhibition of early apoptotic events by Akt/PKB is dependent on the first committed step of glycolysis and mitochondrial hexokinase. Genes Dev 15(11):1406–1418

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  44. Pastorino JG, Hoek JB, Shulga N (2005) Activation of glycogen synthase kinase 3 beta disrupts the binding of hexokinase II to mitochondria by phosphorylating voltage-dependent anion channel and potentiates chemotherapy-induced cytotoxicity. Cancer Res 65(22):10545–10554

    Article  CAS  PubMed  Google Scholar 

  45. Robey IF, Lien AD, Welsh SJ, Baggett BK, Gillies RJ (2005) Hypoxia-inducible factor-1 alpha and the glycolytic phenotype in tumors. Neoplasia 7(4):324–330

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  46. Lum JJ, Bui T, Gruber M, Gordan JD, DeBerardinis RJ, Covello KL, Simon MC, Thompson CB (2007) The transcription factor HIF-1 alpha plays a critical role in the growth factor-dependent regulation of both aerobic and anaerobic glycolysis. Genes Dev 21(9):1037–1049

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  47. Elstrom RL, Bauer DE, Buzzai M, Karnauskas R, Harris MH, Plas DR, Zhuang H, Cinalli RM, Alavi A, Rudin CM, Thompson CB (2004) Akt stimulates aerobic glycolysis in cancer cells. Cancer Res 64(11):3892–3899

    Article  CAS  PubMed  Google Scholar 

  48. Landau BR, Laszlo J, Stengle J, Burk D (1958) Certain metabolic and pharmacologic effects in cancer patients given infusions of 2-deoxy-D-glucose. J Natl Cancer Inst 21(3):475–483

    PubMed  Google Scholar 

  49. Dwarakanath BS, Singh D, Banerji AK, Sarin R, Venkataramana NK, Jalali R, Vishwanath PN, Mohanti BK, Tripathi RP, Kalia VK, Jain V (2009) Clinical studies for improving radiotherapy with 2-deoxy-D-glucose: present status and future prospects. J Cancer Res Ther Suppl 1:S21–S26

    Google Scholar 

  50. Garber K (2010) Oncology’s energetic pipeline. Nat Biotechnol 28(9):888–891

    Article  CAS  PubMed  Google Scholar 

  51. Le A, Cooper CR, Gouw AM, Dinavahi R, Maitra A, Deck LM, Royer RE, Vander Jagt DL, Semenza GL, Dang CV (2010) Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression. Proc Natl Acad Sci U S A 107(5):2037–2042

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  52. Granchi C, Bertini S, Macchia M, Minutolo F (2010) Inhibitors of lactate dehydrogenase isoforms and their therapeutic potentials. Curr Med Chem 17(7):672–697

    Article  CAS  PubMed  Google Scholar 

  53. Courtney KD, Corcoran RB, Engelman JA (2010) The PI3K pathway as drug target in human cancer. J Clin Oncol 28(6):1075–1083

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  54. Shutt DC, O’Dorisio MS, Aykin-Burns N, Spitz DR (2010) 2-deoxy-D-glucose induces oxidative stress and cell killing in human neuroblastoma cells. Cancer Biol Ther 9(11):8953–8961

    Article  Google Scholar 

  55. Aykin-Burns N, Ahmad IM, Zhu Y, Oberley LW, Spitz DR (2009) Increased levels of superoxide and H2O2 mediate the differential susceptibility of cancer cells versus normal cells to glucose deprivation. Biochem J 418(1):29–37

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  56. Le A, Lane AN, Hamaker M, Bose S, Gouw A, Barbi J, Tsukamoto T, Rojas CJ, Slusher BS, Zhang H, Zimmerman LJ, Liebler DC, Slebos RJ, Lorkiewicz PK, Higashi RM, Fan TW, Dang CV (2012) Glucose-independent glutamine metabolism via TCA cycling for proliferation and survival in B cells. Cell Metab 15(1):110–121

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  57. Seltzer MJ, Bennett BD, Joshi AD, Gao P, Thomas AG, Ferraris DV, Tsukamoto T, Rojas CJ, Slusher BS, Rabinowitz JD, Dang CV, Riggins GJ (2010) Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1. Cancer Res 70(22):8981–8987

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  58. Nicklin P, Bergman P, Zhang B, Triantafellow E, Wang H, Nyfeler B, Yang H, Hild M, Kung C, Wilson C, Myer VE, MacKeigan JP, Porter JA, Wang YK, Cantley LC, Finan PM, Murphy LO (2009) Bidirectional transport of amino acids regulates mTOR and autophagy. Cell 136(3):521–534

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  59. Deberardinis RJ, Mancuso A, Daikhim E, Nissim I, Yudkoff M, Wehrli S, Thompson CB (2007) Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc Natl Acad Sci U S A 104(49):19345–19350

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  60. Yuneva M, Zamboni N, Oefner P, Sachidanandam R, Lazebnik Y (2007) Deficiency in glutamine but not glucose induces MYC-dependent apoptosis in human cells. J Cell Biol 78(1):93–105

    Article  Google Scholar 

  61. Wise DR, De Berardinis RJ, Mancuso A, Sayed N, Zhang XY, Pfeiffer HK, Nissim I, Daikhin E, Yudkoff M, McMahon SB, Thompson CB (2008) Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc Natl Acad Sci U S A 105(48):18782–18787

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  62. Gao P, Tchernyshyov I, Chang TC, Lee YS, Kita K, Ochi T, Zeller KI, De Marzo AM, Van Eyk JE, Mendell JT, Dang CV (2009) c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature 458(7239):762–765

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  63. Cheng T, Sudderth J, Yang C, Mullen AR, Jin ES, Mates JM, DeBerardinis RJ (2011) Pyruvate carboxylase is required for glutamine-independent growth of tumor cells. Proc Natl Acad Sci U S A 108(21):8674–8679

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  64. Kaadige MR, Looper RE, Kamalanaadhan S, Ayer DE (2009) Glutamine-dependent anapleurosis dictates glucose uptake and cell growth by regulating MondoA transcriptional activity. Proc Natl Acad Sci U S A 106(35):14878–14883

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  65. Mitsuishi Y, Taguchi K, Kawatani Y, Shibata T, Nukiwa T, Aburatani H, Yamamoto M, Motohashi H (2012) Nrf2 redirects glucose and glutamine into anabolic pathways in metabolic reprogramming. Cancer Cell 22(1):66–79

    Article  CAS  PubMed  Google Scholar 

  66. Kuhajda FP, Jenner K, Wood FD, Hennigar RA, Jacobs LB, Dick JD, Pasternack GR (1994) Fatty acid synthesis: a potential selective target for antineoplastic therapy. Proc Natl Acad Sci U S A 91(14):6379–6383

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  67. Menendez JA, Lupu R (2007) Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer 7(10):763–777

    Article  CAS  PubMed  Google Scholar 

  68. Zha S, Ferdinandusse S, Hicks JL, Denis S, Dunn TA, Wanders RJ, Luo J, De Marzo AM, Isaacs WB (2005) Peroxisomal branched chain fatty acid beta-oxidation pathway is upregulated in prostate cancer. Prostate 63(4):316–323

    Article  CAS  PubMed  Google Scholar 

  69. Liu Y (2006) Fatty acid oxidation is a dominant bioenergetic pathway in prostate cancer. Prostate Cancer Prostatic Dis 9(3):230–234

    Article  CAS  PubMed  Google Scholar 

  70. Pike LS, Smift AL, Croteau NJ, Ferrick DA, Wu M (2011) Inhibition of fatty acid oxidation by etomoxir impairs NADPH production and increases reactive oxygen species resulting in ATP depletion and cell death in human glioblastoma cells. Biochim Biophys Acta 1807(6):726–734

    Article  CAS  PubMed  Google Scholar 

  71. Harper ME, Antoniou A, Villalobos-Menuey E, Russo A, Trauger R, Vendemelio M, George A, Bartholomew R, Carlo D, Shaikh A, Kupperman J, Newell EW, Bespalov IA, Wallace SS, Liu Y, Rogers JR, Gibbs GL, Leahy JL, Camley RE, Melamede R, Newell MK (2002) Characterization of a novel metabolic strategy used by drug-resistant tumor cells. FASEB J 16(12):1550–1557

    Article  CAS  PubMed  Google Scholar 

  72. Samudio I, Harmancey R, Fiegl M, Kantarjian H, Konopleva M, Korchin B, Kaluarachchi K, Bornmann W, Duvvuri S, Taegtmeyer H, Andreeff M (2010) Pharmacologic inhibition of fatty acid oxidation sensitizes human leukemia cells to apoptosis induction. J Clin Invest 120(1):142–156

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  73. Zaugg K, Yao Y, Reilly PT, Kannan K, Kiarash R, Mason J, Huang P, Sawyer SK, Fuerth B, Faubert B, Kalliomaki T, Elia A, Luo X, Nadeem V, Bungard D, Yalavarthi S, Growney JD, Wakeham A, Moolani Y, Silvester J, Ten AY, Bakker W, Tsuchihara K, Berger SL, Hill RP, Jones RG, Tsao M, Robinson MO, Thompson CB, Pan G, Mak TW (2011) Carnitine palmitoyltransferase 1 C promotes cell survival and tumor growth under conditions of metabolic stress. Genes Dev 25(10):1041–1051

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  74. Niemen KM, Kenny HA, Penicka CV, Ladanyi A, Buell-Gutbrod R, Zilihardt MR, Romero IL, Carey MS, Mills GB, Hotamisligil GS, Yamada SD, Peter ME, Gwin K, Lengyel E (2011) Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat Med 17(11):1498–1503

    Article  Google Scholar 

  75. Pizer ES, Wood FD, Pasternack GR, Kuhajda FP (1996) Fatty acid synthase (FAS): a target for cytotoxic antimetabolites in HL60 promyelocytic leukemia cells. Cancer Res 56(4):745–751

    CAS  PubMed  Google Scholar 

  76. Duarte NC, Becker SA, Jamshidi N, Thiele I, Mo ML, Vo TD, Srivas R, Palsson BO (2007) Global reconstruction of the human metabolic network based on genomic and bibliomic data. Proc Natl Acad Sci U S A 104(6):1777–1782

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  77. Jain M, Nilsson R, Sharma S, Madhusudhan N, Kitami T, Souza AL, Kafri R, Kirschner MW, Clish CB, Mootha VK (2012) Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation. Science 336(6064):1040–1044

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  78. Kriegler MP, Pawlowski AM, Livingston DM (1981) Cysteine auxotrophy of human leukemic lymphoblasts is associated with decreased amounts of intracellular cystathionase messenger ribonucleic acid. Biochemistry 20(5):1312–1318

    Article  CAS  PubMed  Google Scholar 

  79. Ensor CM, Holtsberg FW, Bomalaski JS, Clark MA (2002) Pegylated arginine deiminase (ADi-SS PEG 20,000 mw) inhibits human melanomas and hepatocellular carcinomas in vitro and in vivo. Cancer Res 62(19):5443–5450

    CAS  PubMed  Google Scholar 

  80. Watson M, Roulston A, Belec L, Billot X, Marcellus R, Bedard D, Bernier C, Branchaud S, Chan H, Dairi K, Gilbert K, Goulet D, gratton MO, Isakau H, Jang A, Khadir A, Koch E, Lavoie M, Lawless M, Nguyen M, Paquette D, Turcotte E, Berger A, Mitchell M, Shore GC, Beauparlant P (2009) The small molecule GMX1778 is a potent inhibitor of NAD + biosynthesis: strategy for enhanced therapy in nicotinic acid phosphoribosyltransferase 1-deficient tumors. Mol Cell Biol 29(21):5872–5888

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  81. Possemato R, Marks KM, Shaul YD, Pacold ME, Kim D, Birsoy K, Sethumadhavan S, Woo HK, Jang HG, Jha AK, Chen WW, Barrett FG, Stransky N, Tsun ZY, Cowley GS, Barretina J, Kalaany NY, Hsu PP, Ottina K, Chan AM, Yuan B, Garraway LA, Root DE, Mino-Kenudson M, Brachtel EF, Driggers EM, Sabatini DM (2011) Functional genomics reveal that the serine synthesis pathway is essential in breast cancer. Nature 476(7360):346–360

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  82. Locasale JW, Grassian AR, Melman T, Lyssiotis CA, Mattaini KR, Bass AJ, Heffron G, Metallo CM, Muranen T, Sharfi H, Sasaki AT, Anastasiou D, Mullarky E, Vokes NI, Sasaki M, Beroukhim R, Stephanopoulos G, Ligon AH, Meyerson M, Richardson AL, Chin L, Wagner G, Asara JM, Brugge JS, Cantley LC, Vander Heiden MG (2011) Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis. Nat Genet 43(9):869–874

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  83. Frezza C, Zheng L, Folger O, Rajagopalan KN, MacKenzie ED, Jerby L, Micaroni M, Chaneton B, Adam J, Hedley A, Kalna G, Tomlinson IP, Pollard PJ, Watson DG, DeBerardinis RJ, Shlomi T, Ruppin E, Gottlieb E (2011) Haem oxygenase is synthetically lethal with the tumour suppressor fumarate hydratase. Nature 477(7363):225–228

    Article  CAS  PubMed  Google Scholar 

  84. Fantom2Metabolome. http://fantom2.gsc.riken.go.jp/metabolome

  85. Zhang XD (2011) Illustration of SSMD, Z score, SSMD*, z* score and t statistic for hit selection in RNAi high-throughput screens. J Biomol Screen 16(7):775–785

    Article  PubMed  Google Scholar 

  86. Lin LZ, Lin J (2011) Antabuse (disulfiram) as an affordable and promising anticancer drug. Int J Cancer 129(5):1285–1286

    Article  CAS  PubMed  Google Scholar 

  87. Kontos CK, Papadopoulos IN, Fragoulis EG, Scorilas A (2010) Quantitative expression analysis and prognostic significance of L-DOPA decarboxylase in colorectal adenocarcinoma. Br J Cancer 102(9):1384–1390

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  88. Wafa LA, Cheng H, Rao MA, Nelson CC, Cox M, Hirst M, Sadowski I, Rennie PS (2003) Isolation and identification of L-dopa decarboxylase as a protein that binds to and enhances transcriptional activity of the androgen receptor using the repressed transactivator yeast two-hybrid system. Biochem J 375(Pt 2):373–383

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  89. Habibi D, Ogloff N, Jalili RB, Yost A, Weng AP, Ghahary A, Ong CJ (2012) Borrelidin, a small molecule nitrile-containing macrolide inhibitor of threonyl-tRNA synthetase, is a potent inducer of apoptosis in acute lymphoblastic leukemia. Invest New Drugs 30(4):1361–1370

    Article  CAS  PubMed  Google Scholar 

  90. Teperino R, Schoonjans K, Auwerx J (2010) Histone methyl transferases and demethylases: can they link metabolism and transcription? Cell Metab 12(4):321–327

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  91. Albaugh BN, Arnold KM, Denu JM (2011) KAT(ching) metabolism by the tail: insight into the links between lysine acetyltransferases and metabolism. Chem Biochem 12(2):290–299

    CAS  Google Scholar 

  92. Rajendran P, Williams DE, Ho E, Dashwood RH (2011) Metabolism as a key to histone deacetylase inhibition. Crit Rev Biochem Mol Biol 46(3):181–199

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  93. Hanover JA, Krause MW, Love DC (2012) Bittersweet memories: linking metabolism to epigenetics through O-GlcNAcylation. Nat Rev Mol Cell Biol 13(5):312–321

    Article  CAS  PubMed  Google Scholar 

  94. Pearce EL (2010) Metabolism in T cell activation and differentiation. Curr Opin Immunol 22(3):314–320

    Article  CAS  PubMed  Google Scholar 

  95. Zhou W, Choi M, Margineantu D, Margaretha L, Hesson J, Cavanaugh C, Blau CA, Horwitz MS, Hockenbery D, Ware C, Ruohola-Baker H (2012) HIF alpha induced switch from bivalent to exclusively glycolytic metabolism during ESC-to-EpiSC/hESC transition. EMBO J 31(9):2103–2116

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  96. Ward PS, Patel J, Wise DR, Abdel-Wahab O, Bennett BD, Coller HA, Cross JR, Fantin VR, Hedvat CV, Perl AE, Rabinowitz JD, Carroll M, Su SM, Sharp KA, Levine RL, Thompson CB (2010) The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 17(3):225–234

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  97. Xu W, Yang H, Liu Y, Yang Y, Wang P, Kim SH, Ito S, Yang C, Wang P, Xiao MT, Liu LX, Jiang WQ, Liu J, Zhang JY, Wang B, Frye S, Zhang Y, Xu YH, Lei QY, Guan KL, Zhao SM, Xiong Y (2011) Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases. Cancer Cell 19(1):17–30

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  98. Chowdhury R, Yeoh KK, Tian YM, Hillringhaus L, Bagg EA, Rose NR, Leung IK, Li XS, Woon EC, Yang M, McDonough MA, King ON, Clifton IJ, Klose RJ, Claridge TD, Ratcliffe PJ, Schofield CJ, Kawamura A (2011) The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases. EMBO Rep 12(5):463–469

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  99. Lu C, Ward PS, Kapoor GS, Rohle D, Turcan S, Abdel-Wahab O, Edwards CR, Khanin R, Figueroa ME, Melnick A, Wellen KE, O’Rourke DM, Berger SL, Chan TA, Levine RL, Mellinghoff IK, Thompson CB (2012) IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature 483(7390):474–478

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  100. Turcan S, Rohle D, Goenka A, Walsh LA, Fang F, Yilmaz E, Campos C, Fabius AW, Lu C, Ward PS, Thompson CB, Kaufman A, Guryanova O, Levine R, Heguy A, Viale A, Morris LG, Huse JT, Mellinghoff IK, Chan TA (2012) IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 483(7390):479–483

    Article  CAS  PubMed Central  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Clinical Research Seattle, Fred Hutchinson Cancer Research Center, WA, USA

    David M Hockenbery, Mark Tom, Cori Abikoff & Daciana Margineantu

Authors
  1. David M Hockenbery
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mark Tom
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Cori Abikoff
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Daciana Margineantu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David M Hockenbery .

Editor information

Editors and Affiliations

  1. Department of Medicine, University of Pittsburgh Division of Hematology/Oncology, Pittsburgh, Pennsylvania, USA

    Daniel E. Johnson

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+Business Media New York

About this chapter

Cite this chapter

Hockenbery, D.M., Tom, M., Abikoff, C., Margineantu, D. (2013). The Warburg Effect and Beyond: Metabolic Dependencies for Cancer Cells. In: Johnson, D. (eds) Cell Death Signaling in Cancer Biology and Treatment. Cell Death in Biology and Diseases. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4614-5847-0_2

Download citation

Publish with us

Policies and ethics

Search

Navigation